Imclone to seek Erbitux OK for head, neck cancer

	Tweet

ImClone Systems Inc. and Bristol-Myers Squibb Co. said on Tuesday they plan by the second quarter of 2005 to ask U.S. regulators to approve use of their Erbitux colon cancer drug as a treatment for head and neck cancer.

The U.S. drugmakers, which split profits from the injectable drug, said they would ask the U.S. Food and Drug Administration to approve its use in combination with radiation against head and neck cancer.

ImClone and Bristol-Myers said they have already discussed their plans with the FDA and are hopeful the agency will decide on their application on a priority basis, meaning within six months rather than the agency’s typical year-long review period.

The FDA in February approved Erbitux for use against colon cancer following a controversial insider share-trading scandal that landed former ImClone Chief Executive Sam Waksal in prison.

Researchers in June released clinical data showing that Erbitux controlled head and neck cancer better than radiation alone and helped some patients live longer.

Copyright © 2004 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable

RELATED STORIES:
Immune system may help cancer cells hide: study   US cancer institute starts nanotechnology drive   Two Genes That Drive Aggressive Brain Cancers Discovered   Cancer docs say Medicare won’t cover drug costs   Laser light may be able to detect diseases on the breath   Disease diagnosis in just 15 minutes   Children with cancer often use alternative medicine   Ovarian cancer risk increases with estrogen use   Vets to get cancer care in Indy   Breast tumors more aggressive in African Americans   Fear cancer will increase   Alzheimer’s Disease May Protect Against Cancer and Vice Versa

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]